- 4th Visit at 17 Years of Cohort STANISLAS - Stanislas Ancillary Study ESCIF

MAIN STUDY Follow-up visit No. 4 is currently being scheduled, and is planned between 2011 and 2016.

Objectives:

• Conduct a fourth visit, in 2011-2016, enabling a follow-up at 17 years of the cohort population.
• Enrich the sample collection with new biobanks and clinical phenotyping of the cohort by conducting selected specific investigations and supported by specific scientific hypotheses and protocols
• Evaluate the long-term (follow-up, monitoring) of clinical, biological, morphological data by analyzing:

• The influence of aging (average age of parents in 1993: 45 years and in 2010-2012: 62 years).
• The incidence and changes in prevalence of cardiovascular risk factors comprising the metabolic syndrome (MS), and their familial segregation, since as early as the second visit, in some one hundred families, at least one family member presented a MS according the definition of the NCEP-ATPIII. Approximately 20% of adults had high blood pressure (hypertension), and 50% had a body mass index above 25 kg/m2.
• The genetic and environmental determinants, through a multifaceted approach including familial segregation and candidate genes, the progression of cardiovascular risk and the incidence of cardiovascular diseases (vascular and coronary diseases, heart failure).

Methodology, Organization:

All Cohort members will be contacted to participate in this fourth visit. The data collected will be identical to those collected during the previous visits. However, they will be enriched with new clinical phenotyping conducted at the CIC (principal investigator Prof. Zannad): collection of blood and urine samples (DNA, RNA, lymphocytic extracts, plasma biobank, urology biobank), and morphological investigations (electrocardiogram, echocardiography, carotid echotracking, arterial stiffness, systolic pressure index, abdominal aortic ultrasound). Based on previous participation rates, the recruitment of 2,000 participants (500 families) is possible.

Expected Results:

This reconvening, for the follow-up at 17 years of the Stanislas Cohort, unique in its familial nature and having already contributed in a very significant manner in terms of knowledge generated, will enable in addition to the long-term continuation of its initial objectives (gene-environment interactions and cardiovascular diseases : Sophie Visvikis-Siest) to identify more specifically the natural history of the evolution of cardiovascular risk factors, including metabolic syndrome and its components as well as the incidence and transition mechanisms toward common cardiovascular diseases, notably vascular and coronary diseases and heart failure.

ANCILLARY STUDY

Detailed description of the ESCIF ancillary study - Dr. BONNEMAINS :

Objectives :

• to compare cardiac functional indices measured in MRI with the GRICS technique with equivalent indices measured with echocardiography.
• to assess inter-observer reproducibility of echography and MRI.

Organization :

76 subjects from the Stanislas cohort will be included prospectively in two groups according to the echocardiographic strains and tissue Doppler velocities acquired during echocardiography : 38 subjects with normal indices, and 38 with altered indices. Each subject will be proposed an MRI examination with the GRICS technique the same day to assess the same indices.

Study design = interventional: MRI. Prospective Number of groups: 2 Enrollment: 76 Last inclusion in the ESCIF study : 23/09/2014

SUBSTUDY : PHRC I 2013 - BioSe-PreIC - Dr HUTTIN : diagnostic performance of circulating biomarkers in early screening of heart failure Design : non interventionnal study

Main objective : Determine the contribution, in addition (ontop of ) of the subject's clinical characteristics, of circulating biomarkers assays (Gal-3, PIIINP, ST2) in a general population to screen early stages of heart failure (Stage B: asymptomatic patients with structural abnormalities) validated by trans-thoracic echocardiography (diastolic function and left ventricular mass)

Inclusion crieria :

Subjects participating to the 4th visit of the STANISLAS cohort

Subjets over 40 years old

Non-inclusion criteria :

Blood sample or echocardiography unavailable

Known cardiopathy

Modarate to severe sympptoms linked to heart failure

Présence of an abnormal diastolic function (E/Ea ratio above 8) and/or left ventricular hypertrophy (left ventricular mass above 125 g/m² for men and 110 g/m² for women).

Inclusion criteria

• Patient having taken part in the STANISLAS troop,
• At least 18 years old,
• Written and signed enlightened assent,
• Ensured social

Exclusion criteria

• Patient unable to understand the informed consent,
• patient under legal protection

STANISLAS ancillary study:

Study population = subgroup of 76 subjects from the Stanislas cohort

Eligibility:

being member of the Stanislas cohort and participating to 4th visit Specific written and signed enlightened consent for the ESCIF study

Exclusion:

contraindications for MRI examination, possibility of pregnancy